Sensorion SA Total Liabilities
Sensorion SA total liabilities. Based on the latest financial reports, Sensorion SA (ALSEN) has total liabilities worth €13.41 Million EUR (≈ $15.68 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ALSEN financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sensorion SA (2011–2025)
Total liabilities of Sensorion SA from 2011 to 2025. This chart illustrates how Sensorion SA's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Sensorion SA to see how much of total assets are deployed in long-term investments.
Sensorion SA Competitors by Total Liabilities
The table below lists competitors of Sensorion SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grammer AG
XETRA:GMM
|
Germany | €1.43 Billion |
|
Lake Superior Acquisition Corp. Class A Ordinary Shares
NASDAQ:LKSP
|
USA | $4.92 Million |
|
Financiera Independencia S.A.B. de C.V. SOFOM E.N.R
MX:FINDEP
|
Mexico | MX$5.78 Billion |
|
Victoria Investama Tbk
JK:VICO
|
Indonesia | Rp29.92 Trillion |
|
Tah Kong Chemical Industrial
TWO:4706
|
Taiwan | NT$132.58 Million |
|
Adriano Care SOCIMI SAU
MC:YADR
|
Spain | €132.09 Million |
|
Freelance.Com
PA:ALFRE
|
France | €364.30 Million |
|
Archimedes Tech SPAC Partners II Co. Ordinary Shares
NASDAQ:ATII
|
USA | $8.18 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Sensorion SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sensorion SA total assets.
Liquidity & Leverage Metrics
Sensorion SA Total Liabilities Ratios Explained
Sensorion SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.24 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sensorion SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sensorion SA (2011–2025)
The table below shows the annual total liabilities of Sensorion SA from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €13.41 Million ≈ $15.68 Million |
-21.77% |
| 2024-12-31 | €17.14 Million ≈ $20.04 Million |
+29.57% |
| 2023-12-31 | €13.23 Million ≈ $15.46 Million |
-22.47% |
| 2022-12-31 | €17.06 Million ≈ $19.94 Million |
+13.47% |
| 2021-12-31 | €15.03 Million ≈ $17.58 Million |
+57.85% |
| 2020-12-31 | €9.52 Million ≈ $11.13 Million |
-61.72% |
| 2019-12-31 | €24.88 Million ≈ $29.09 Million |
+317.68% |
| 2018-12-31 | €5.96 Million ≈ $6.96 Million |
+55.06% |
| 2017-12-31 | €3.84 Million ≈ $4.49 Million |
+17.86% |
| 2016-12-31 | €3.26 Million ≈ $3.81 Million |
-11.91% |
| 2015-12-31 | €3.70 Million ≈ $4.33 Million |
+47.11% |
| 2014-12-31 | €2.52 Million ≈ $2.94 Million |
+7.83% |
| 2013-12-31 | €2.33 Million ≈ $2.73 Million |
+561.52% |
| 2012-12-31 | €352.61K ≈ $412.24K |
+67.50% |
| 2011-12-31 | €210.51K ≈ $246.11K |
-- |
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutat… Read more